• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 2Inclusion and Exclusion Criteria for Primary Studies

Inclusion Criteria
DesignPublished RCTs
PopulationPatients diagnosed with RRMSa
Intervention
  • Disease-modifying agents
    [filled square]

    Currently available (formulations and doses approved and available in Canada only will be included)

    *

    Fingolimod — oral

    *

    Interferon beta-1a — injectable

    *

    Interferon beta-1b — injectable

    *

    Natalizumab — injectable

    *

    Glatiramer acetate — injectable

    [filled square]

    Emerging

    *

    Teriflunomide — oral

    *

    Dimethyl fumarate — oral

    *

    Alemtuzumab — injectable

  • Placebo
Outcomes
  • Relapse
  • Disability
  • MRI changes
  • Quality of life
  • Deaths
  • Serious adverse events
  • Discontinuation of treatment because of adverse events
  • Adverse events
Exclusion Criteria
Studies in languages other than English
Non-randomized studies
Follow-up or extension studies
Preliminary results in abstract form

MRI = magnetic resonance imaging; MS = multiple sclerosis; RCT = randomized controlled trials; RRMS = relapsing-remitting MS.

a

RCTs having a mixed population (i.e., persons with primary-progressive or secondary-progressive MS in addition to persons with RRMS) will be included for completeness if the RRMS population is greater than 50% of the total population.

RCTs having a mixed population (i.e., persons with primary-progressive or secondary-progressive MS in addition to persons with RRMS) will be included for completeness if the RRMS population is greater than 50% of the total population.

From: 3, METHODS

Cover of Management of Relapsing-Remitting Multiple Sclerosis
Management of Relapsing-Remitting Multiple Sclerosis [Internet].
CADTH Therapeutic Review, No. 1.2.
Copyright © CADTH March 2013.

You are permitted to make copies of this document for non-commercial purposes provided it is not modified when reproduced and appropriate credit is given to CADTH. You may not otherwise copy, modify, translate, post on a website, store electronically, republish or redistribute any material from the website in any form or by any means without the prior written permission of CADTH.

Please contact CADTH’s Vice-President of Corporate Services at ac.htdac@secivresetaroproc with any inquiries about this notice or other legal matters relating to CADTH’s services.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.